Atypical antipsychotic drugs: beyond acute psychosis, new directions

Bibliography

• AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders (Edition 4). American Psychiatric Association Press, Washington DC, USA (1994).
   Google Scholar
• VVYATT RJ, HENTER I, LEARY MC: An economic evaluation of schizophrenia - 1991. Soc. Psychiatry Psychiatr. Epidemiol. (1995) 30:196–205.
   PubMed Web of Science ®Google Scholar
• WILLIAMS R, DICKSON RA: Economics of schizophrenia. Can. J. Psychiatry (1995) 40 (Suppl. 2) S60–S67.
   PubMedGoogle Scholar
• PSYCHIATRY GLOBAL MEDICAL CONFERENCE: New directions in understanding and treating schizophrenia. J. Clin. Psychiatry Monograph Series (1997) 15:2–17.
   Web of Science ®Google Scholar
• YUNG AR, MCGORRY PD: The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr. Bull. (1996) 22:353–370.
   PubMed Web of Science ®Google Scholar
• FINDLING RL, GRCEVICH SJ, LOPEZ I, SCHULZ SC: Antipsychotic medications in children and adolescents. J. Clin. Psychiatry (1996) 57 (Suppl. 9) :19–23.
   PubMedGoogle Scholar
• BUCKLEY PF: Treatment of schizophrenia: let's talk dollars and cents. Am. J. Managed Care (1998) 4:369–383.
   PubMed Web of Science ®Google Scholar
• •Good review about the economics of treatment of schizophrenia.
   Google Scholar
• CASEY DE: Side effect profiles of new antipsychotic agents. J. Clin. Psychiatry (1996) 57\(Suppl. 11) :40–45.
   PubMedGoogle Scholar
• •Good review of the side-effects associated with schizophrenia drug therapies.
   Google Scholar
• Casey DE, Christensen AV (Eds.), Springer, Berlin (1988):74–93.
   Google Scholar
• Neuroleptic Non-compliance in Schizophrenia. Weiden P, Mann JJ, Haas G et al. (Eds.), Raven Press, Inc., New York, USA (1991).
   Google Scholar
• HELLEWELL JSE: Attitudes towards the treatment of schizophrenia and perceptions of antipsychotics side effects: a multinational survey of psychiatrists, nurses, patients and caregivers. llth Annual Congress of the European College of Neuropsychopharmacology. Paris, France (1998).
   Google Scholar
• WEIDEN P, MANN JJ, HAAS G, et al.: Clinical non-recognition of neuroleptic-induced movement disorders: a cautionary study. Am. J. Psychiatry (1987) 144:1148–1153.
   PubMed Web of Science ®Google Scholar
• BARNES TRE, KIDGER T, GORE SM: Tardive dyskinesia: a 3-year follow-up study. Psychological Med. (1983) 13:71–81.
   PubMed Web of Science ®Google Scholar
• SALTZ BL, WOERNER MG, KANE JM, et al.: Prospective study of tardive dyskinesia incidence in the elderly. JAMA (1991) 266:2402–2406.
   PubMed Web of Science ®Google Scholar
• WOERNER MG, ALVIR JMJ, SALTZ BL, LIEBERMAN JA, KANE JM: Prospective study of tardive dyskinesia in the elderly; rates and risk factors. Am. J. Psychiatry (1998) 155:1521–1528.
   PubMed Web of Science ®Google Scholar
• TUMA AH, MAY PRA: And if that doesn't work, what next A study of treatment failures in schizophrenia. J. Nerv. Ment. Dis. (1979) 167:566–571.
   PubMed Web of Science ®Google Scholar
• CASEY DE: Motor and mental aspects of acute extrapyramidal syndromes. Acta Psychiatr. Scand. (1994) 89:14–20.
   PubMed Web of Science ®Google Scholar
• ASCHAUER HN, SCHONBECK G, LANGER G, et al.: Plasma concentrations of haloperidol and prolactin and clinical outcome in acutely psychotic patients. Pharmacopsychiatry (1988) 21:246–251.
   PubMed Web of Science ®Google Scholar
• GHADIRIAN AM, CHOIUNARD G, ANNABLE L: Sexual dysfunction and plasmaprolactin levels in neuroleptic-treated schizophrenic outpatients. J. Nerv. Ment. Dis. (1982) 170:463–467.
   PubMed Web of Science ®Google Scholar
• ATAYA K, MERCADO A, KARTAGINER J, ABBASI A, MOGHISSI KS: Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia. Fertil. Steril. (1988) 50:876–881.
   PubMed Web of Science ®Google Scholar
• KLIBANSKI A, NEER RM, BEITINS IZ, RIDGWAY EC, ZERVAS NT, MCARTHUR JVV: Decreased bone density in hyperprolactinemic women. New Engl. J. Med. (1980) 303:1511–1514.
   PubMed Web of Science ®Google Scholar
• JOHNSTON DG, HAIGH J, PRESCOTT RW, et al.: Prolactin secretion and biological activity in females with galactorrhea and normal circulating prolactin concentrations at rest. Clin. Endocrinol. (1985) 22:661–678.
   PubMed Web of Science ®Google Scholar
• SAX KW, STRAKOWSKI S, KECK PE, Jr.: Attentional improvement following quetiapine fumarate treatment in schizophrenia. Schizophr. Res. (1998) 33:151–155.
   PubMed Web of Science ®Google Scholar
• ARVANITIS LA, MILLER BG, THE SEROQUEL TRIAL 13 STUDY GROUP: Multiple fixed doses of `Seroquer (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol. Psychiatry (1997) 42:233–246.
   PubMed Web of Science ®Google Scholar
• •Pivotal study with quetiapine.
   Google Scholar
• SMALL JG, HIRSCH SR, ARVANITIS LA, MILLER BG, LINK CGG, THE SEROQUEL STUDY GROUP: Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch. Gen. Psychiatry (1997) 54:549–557.
   PubMed Web of Science ®Google Scholar
• BRAR JS, CHENGAPPA KN, PAREPALLY H, et al.: The effects of clozapine on negative symptoms in patients with schizophrenia with minimal positive symptoms. Ann. Clin. Psychiatry (1997) 9:227–234.
   PubMedGoogle Scholar
• TOLLEFSON GD, SANGER TM: Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled trial with olanzapine. Am. J. Psychiatry (1997) 154:466–474.
   PubMed Web of Science ®Google Scholar
• CARMAN J, PEUSKENS J, VANGENEUGDEN A: Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int. Clin. Psychopharmacol. (1995) 10:207–213.
   PubMed Web of Science ®Google Scholar
• MOLLER JJ, MULLER H, BORISON RL, SCHOOLER NR, CHOUINARD G: A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. Eur. Arch. Psychiatry Clin. Neurosci. (1995) 245:45–49.
   PubMed Web of Science ®Google Scholar
• CONLEY R, KELLY D, LOVE R: Risperidone use in Maryland: dosing trends and rehospitalization rates. Biol. Psychiatry (1998) 43 (Suppl. 8):399A.
   Google Scholar
• KANE JM: New choices in antipsychotic therapy. J. Clin. Psychiatry (1996) 57(Suppl.):427–438.
   PubMedGoogle Scholar
• •A good review of antipsychotic therapy.
   Google Scholar
• ALLEN RL, WALKER Z, D'ATH PJ, KATONA CL: Risperidone for psychotic and behavioral symptoms in Lewy body dementia. Lancet (1995) 346:185.
   PubMed Web of Science ®Google Scholar
• FACTOR SA, BROWN D, MOLHO ES, PODSKALNY GD: Clozapine: a two year open trial in Parkinson's disease patients with psychosis. Neurology (1994) 44:544–546.
   PubMed Web of Science ®Google Scholar
• JUNCOS JL, EVATT ML, JEWART D: Long-term effects of quetiapine fumarate in parkinsonism complicated by psychosis. Neurology (1998) 50:70–71.
   Google Scholar
• PARSA MA, BASTANI B: Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson's disease. J. Neuropsychiatry (1998)10:216-219.
   Google Scholar
• JUNCOS JL: Management of psychotic aspects of Parkinson's disease. J. Clin. Psychiatry (In Press).
   PubMedGoogle Scholar
• ROSENFELD MJ, FRIEDMAN JH, JACQUES C: Quetiapine pilot trial in dopaminometic psychosis (DP) in Parkinson's disease (PD). 5th International Congress of Parkinson's Disease & Movement Disorders. New York, NY, USA (1998).
   Google Scholar
• TOHEN M, ZARATE CAJ: Antipsychotic agents and bipolar disorder. J. Clin. Psychiatry (1998) 59 (Suppl. 1):38–48.
   PubMed Web of Science ®Google Scholar
• ZARATE CA, Jr., NARENDRAN R, TOHEN M, et al.: Clinical predictors of acute response with olanzapine in psychotic mood disorders. J. Clin. Psychiatry (1998) 59:24–28.
   PubMed Web of Science ®Google Scholar
• CANTILLON M: Quetiapine fumarate: effects on hostility, aggression and affective symptoms in patients with acute schizophrenia. 38th Annual Meeting of the New Clinical Drug Evaluation Unit Program (NCDEU). Boca Raton, Finland (1998).
   Google Scholar
• GHAEMI SN, SACHS GS: Long-term risperidone treatment in bipolar disorder: 6-month follow up. Int. Clin. Psychopharmacol. (1997) 12:333–338.
   PubMed Web of Science ®Google Scholar
• DICKSON RA, GUPTA S: Antipsychotic-induced hyperprolactinemia causes serious adverse effects. J. Psychotic Disorders (1997) 2:3–17.
   Google Scholar
• •A good discussion of the issues surrounding hyperprolactinemia.
   Google Scholar
• KWA HG, CLETON F, WANG DY, et al.: A prospective study of plasma prolactin levels and subsequent risk of breast cancer. Int. J. Cancer (1981) 28:673–676.
   PubMed Web of Science ®Google Scholar
• HALBREICH U, PALTER S: Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes. Schizophr. Bull. (1996) 22:447–454.
   PubMed Web of Science ®Google Scholar
• KALALI A, HELLEWELL J, GOLDSTEIN J, LANGHAM S: A multinational survey of patients' satisfaction with long-term `Seroquef (quetiapine fumarate). 21st Congress of the Collegium Internationale Neuro-psychopharmacolegicum. Glasgow, Scotland, UK (1998).
   Google Scholar
• DEQUARDO JR, TANDON R: Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia J. Psychiatr. Res. (1998) 32:229–242.
   PubMed Web of Science ®Google Scholar
• •An excellent review of the current atypical antipsychotics.
   Google Scholar
• MELTZER HY, COLA P, WAY L, et al.: Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am. J. Psychiatry (1993) 150:1630–1638.
   PubMed Web of Science ®Google Scholar
• ADDINGTON DE, JONES B, BLOOM D, CHOUINARD G, REMINGTON G, ALBRIGHT P: Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin. Ther. (1993) 15:917–926.
   PubMed Web of Science ®Google Scholar
• CHOUINARD G, ALBRIGHT PS: Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. J. Clin. Psychopharmacol. (1997) 17:298–307.
   PubMed Web of Science ®Google Scholar
• •A pivotal study of risperidone.
   Google Scholar
• COLLABORATIVE WORKING GROUP ON CLINICAL TRIAL EVALUATIONS: Adverse effects of the atypical antipsychotics. J. Clin. Psychiatry (1998) 59 (Suppl. 12):17–22.
   Google Scholar
• ••An excellent collaborative review of the adverse effects of atypical antipsychotics.
   Google Scholar
• WEINBERGER DR: The biological basis of schizophrenia: new directions. J. Clin. Psychiatry (1997) 58\(Suppl. 10):22–27.
   PubMedGoogle Scholar
• WADDINGTON JL: Schizophrenia: developmental neuroscience and pathobiology. Lancet (1993) 341:531–536.
   PubMed Web of Science ®Google Scholar
• VVYATT RJ: Neurodevelopmental abnormalities and schizophrenia. Arch. Gen. Psychiatry (1996) 53:11–15.
   PubMed Web of Science ®Google Scholar
• KIRCH DG: Infection and autoimmunity as etiologic factors in schizophrenia: a review and reappraisal. Schizophr. Bull. (1993) 19:355–370.
   PubMed Web of Science ®Google Scholar
• SUSSER E, NEGEBAUER R, HOEK HW, et al.: Schizophrenia after prenatal famine. Arch. Gen. Psychiatry (1996) 53:25–31.
   PubMed Web of Science ®Google Scholar
• NASRALLAH HA: Neurodevelopmental pathogenesis of schizophrenia. Psychiatr. Clin. North Am. (1993) 16:269–280.
   PubMed Web of Science ®Google Scholar
• KOTRLA KJ, WEINBERGER DR: Brain imaging in schizophrenia. Ann. Rev. Med. (1995) 46:113–122.
   PubMed Web of Science ®Google Scholar
• Shriqui CL, Nasrallah HA (Eds.), American Psychiatric Press, Washington DC, USA (1995)43–60.
   Google Scholar
• NIEDERMIER JA, NASRALLAH HA: New developments in schizophrenia. J. Prac. Psych. Behav. Hlth. (1997) 3:191–201.
   Web of Science ®Google Scholar
• ••A good overview of the treatment of schizophrenia.
   Google Scholar
• Shriqui CL, Nasrallah HA (Eds.), American Psychiatric Press, Washington DC, USA (1995):3–42.
   Google Scholar
• BUCKLEY P: New dimensions in the pharmacologic treatment of schizophrenia and related psychoses. J. Clin. Pharmacol. (1997) 37:363–378.
   PubMed Web of Science ®Google Scholar
• ••An excellent review of the limitations and expectations of antipsychotic medications.
   Google Scholar
• SEEMAN P, TALLERICO T: Antipsychotic drugs which elicit little or no parkinsonian symptoms bind more loosley than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol. Psychiatry (1998) 3:124–134.
   Google Scholar
• KERWIN JR, TAYLOR D: New antipsychotics: a review of their current status and clinical potential. Drugs (1996) 6:71–82.
   Web of Science ®Google Scholar
• MELTZER HY, MATSUBARA S, LEE J-C: The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol. Bull. (1989) 25:390–392.
   PubMed Web of Science ®Google Scholar
• Quitkin FM, Adams DC, Bowden CL et al. (Eds.), Current Medicine, Inc., Philadelphia, USA (1998):120–154.
   Google Scholar
• •A good review of the new antipsychotic medications.
   Google Scholar
• JIBSON M, TANDON R: New atypical antipsychotic medications. J. Psychiatr. Res. (1998) 32:215–228.
   PubMed Web of Science ®Google Scholar
• •A good review of the atypical antipsychotics.
   Google Scholar
• RICHELSON E: Pharmacology of neuroleptics in use in the United States. J. an. Psychiatry (1985) 46:8–14.
   Google Scholar
• ELLENBROEK BA: Treatment of schizophrenia: a clinical and preclinical evaluation on neuroleptic drugs. Pharmacol. Ther. (1993) 57:1–78.
   PubMed Web of Science ®Google Scholar
• KINON BJ, LIEBERMAN JA: Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology (1996) 124:2–34.
   PubMed Web of Science ®Google Scholar
• ARNT J, SKARSFELDT T: Do novel antipsychotics have similar pharmacological characteristics A review of the evidence. Neuropsychopharmacology (1998) 18:63–101.
   PubMed Web of Science ®Google Scholar
• TANDON R, MILNER K, JIBSON M: Antipsychotics from theory to practice; integrating clinical and basic data. J. Clin. Psychiatry (In Press).
   Google Scholar
• •A good review of theoretical and practical understandings of the new antipsychotic medications.
   Google Scholar
• JAUSS M, SCHRODER J, PANTEL J, BACHMANN S, GERDSEN I, MUNDT C: Severe akathisia during olanzapine treatment of acute schizophrenia. Pharmacopsychiatry (1998) 31:146–148.
   PubMed Web of Science ®Google Scholar
• MILLER CH, MOHR F, UMBRICHT D, WOERNER M, FLEISCHHACKER WW, LIEBERMAN JA: The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J. Clin. Psychiatry (1998) 59:69–75.
   PubMed Web of Science ®Google Scholar
• CHOUINARD G, JONES B, REMINGTON G, et al.: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of schizophrenia. J. Clin. Psychopharmacol. (1993) 13:25–40.
   PubMed Web of Science ®Google Scholar
• •The pivotal study of risperidone.
   Google Scholar
• KANE J, HONIGFIELD G, SINGER et al.: Clorazil collaborative study group: clozapine in the treatment-resistant schizophrenic: a double-blind comparison versus chlorpromazine/benztropine. Arch. Gen. Psychiatry (1988) 45:789–796.
   PubMed Web of Science ®Google Scholar
• •The pivotal study of clozapine in treatment-resistant patients.
   Google Scholar
• LEE MA, THOMPSON PA, MELTZER HY: Effects of clozapine on cognitive function in schizophrenia. J. Clin. Psychiatry (1994) 55:82–87.
   PubMed Web of Science ®Google Scholar
• PEUSKENS J: Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br. J. Psychiatry (1995) 166:712–726.
   PubMed Web of Science ®Google Scholar
• DICKSON RA, DALBY JT, WILLIAMS R, EDWARDS AL: Risperidone-induced prolactin elevations in premenopausal women with schizophrenia. Am. J. Psychiatry (1995) 152:1102–1103.
   PubMed Web of Science ®Google Scholar
• BEASLEY CM, Jr., TOLLEFSON G, TRAN P, et al.: Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology (1996) 14:111–123.
   PubMed Web of Science ®Google Scholar
• •The pivotal study of olanzapine.
   Google Scholar
• KURZTHALER I, HUMMER M, KOHL C, MILLER C, FLEISCHHACKER WW: Propranolol treatment of olanzapine-induced akathisia. Am. J. Psychiatry (1997) 154:1316.
   PubMedGoogle Scholar
• BEASLEY CM, SANGER T, SATTERLEE WG, et al.: Olanzapine versus placebo: results of a double-blind fixed-dose trial. Psychopharmacology (1996) 124:159–167.
   PubMed Web of Science ®Google Scholar
• TOLLEFSON GD, BEASLEY CM, TAMURA RN, TRAN PV, POTVIN JH: Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am. J. Psychiatry (1997) 154:1248–1254.
   PubMed Web of Science ®Google Scholar
• HAMILTON SH, REVICKI DA, GENDUSO LA, BEASLEY CM, Jr.: Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology (1998) 18:41–49.
   PubMed Web of Science ®Google Scholar
• FULTON B, GOA KL: Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs (1997) 53:281–298.
   PubMed Web of Science ®Google Scholar
• TRAN P, HAMILTON S, KUNTZ A, et al.: Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J. Clin. Psychopharmacol. (1997) 17:407–418.
   PubMed Web of Science ®Google Scholar
• WIRSHING DA, SPELLBERG BJ, ERHARD SM, MARDER SR: Novel antipsychotics and new onset diabetes. Biol. Psychiatry (1998) 44:778–783.
   PubMed Web of Science ®Google Scholar
• WEIDENOlanzapine: a new 'atypical' antipsychotic. J. Prac. Psychiatry Behav. Hlth.(1997) 3:49–53.
   Google Scholar
• ZYPREXA® [PACKAGE INSERT]: Olanzapine. Eli Lilly & Company, Indianapolis, IN, USA (1996).
   Google Scholar
• BORISON RL, ARVANITIS LA, MILLER BG, THE US SEROQUEL STUDY GROUP: ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J. Clin. Psychopharmacol. (1996) 16:158–169.
   PubMed Web of Science ®Google Scholar
• COPOLOV DL, LINK CGG: A multicentre, double-blind, randomized comparison of ICI 204,636 (SeroquelTm) and haloperidol in the treatment of subjects with acute exacerbation of subchronic or chronic schizophrenia. (In Preparation).
   Google Scholar
• PEUSKENS J, LINK CGG: A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr. Scand. (1997) :255–275.
   Google Scholar
• MCMANUS DQ, ARVANITIS LA, KOWALCYK BB, THE SEROQUEL TRIAL 48 STUDY GROUP: Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. J. Clin. Psychiatry (In Press).
   Google Scholar
• MISRA LK, ERPENBACH JE, HAMLYN H, FULLER WC: Quetiapine: a new atypical antipsychotic. SDJ Med. (1998) 51:189–193.
   Google Scholar
• GOLDBERG RJ, GOLDBERG J: Risperidone for dementia-related disturbed behavior in nursing home residents: a clinical experience. Int. Psychogeriatr. (1997) 9:65–68.
   PubMedGoogle Scholar
• HERRMANN N, RIVARD MF, FLYNN M, WARD C, RABHERU K, CAMPBELL B: Risperidone for the treatment of behavioral disturbances in dementia: a case series. J. Neuropsychiatry Clin. Neurosci. (1998) 10:220–223.
   PubMed Web of Science ®Google Scholar
• MELTZER H: Treating schizophrenia in the millennium. Psychiatric. News. (1998)3.
   Google Scholar
• GEFVERT O, BERGSTROM M, LANGSTROM B, LUNDBERG T, LINDSTROM L, YATES R: Time course of central nervous dopamine-D2 and 5HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology (1998) 135:119–126.
   PubMed Web of Science ®Google Scholar
• CUTLER A, GOLDSTEIN JM, CANTILLON M: Dosing and switching strategies for a dibenzothiazepine, a new class of atypical antipsychotic. (Submitted).
   Google Scholar
• HEGARTY JD, BALDESSARINI RJ, TOHEN M, WATERNAUX C, OEPEN G: One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am. J. Psychiatry (1994) 151:1409–1416.
   PubMed Web of Science ®Google Scholar
• COLLABORATIVE WORKING GROUP ON CLINICAL TRIAL EVALUATIONS: Clinical development of atypical antipsychotics: research design and evaluation. J. Clin. Psychiatry (1998) 59 (Suppl. 12):10–16.
   Google Scholar
• ••A collaborative review of the research design and evaluations of antipsychotic medications.
   Google Scholar
• KECK PE, JR., WILSON DR, STRAKOWSKI SM, et al.: Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder and psychotic mood disorders. J. Clin. Psychiatry (1995) 56:466–470.
   PubMed Web of Science ®Google Scholar